Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor Masitinib.
Bethany D Latham, D Spencer Oskin, Rachel D Crouch...
https://pubmed.ncbi.nlm.nih.gov/36048877/Actively Recruiting
Led by AB Science · Updated on 2025-09-12
495
Participants Needed
56
Research Sites
N/A
Total Duration
Researchers are evaluating the effectiveness and safety of masitinib combined with riluzole compared to a placebo combined with riluzole for treating Amyotrophic Lateral Sclerosis ALS. This phase 3 study focuses on patients diagnosed with probable or definite ALS, aiming to understand how masitinib, a drug that targets cells involved in neuroinflammation, might slow disease progression and affect the nervous systems environment. Participants receive oral masitinib at 3.0 mgkgday twice daily, with dose increases to 4.5 mgkgday after 4 weeks, and for some, an additional increase to 6.0 mgkgday after another 4 weeks. Each dose increase includes safety monitoring. Masitinib is given alongside riluzole, a standard ALS treatment at 50 mg twice daily. The control group receives a matching placebo with riluzole. The study is randomized, double-blind, and includes two different masitinib dose escalation schedules. During the 48-week study period, participants undergo regular assessments including functional rating scales ALSFRS-R, quality of life questionnaires ALSAQ-40, survival and progression monitoring, lung function tests FVC, and muscle strength measurements HHD. Researchers measure changes in combined function and survival scores. Safety is closely monitored throughout, with follow-up extending up to 36 months for disease progression or death. Total participation includes baseline screening, treatment, and long-term observation.
CONDITIONS
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
C
Clinical Study Coordinator
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
AB Science
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Masitinib + Riluzole | Placebo + Riluzole | Riluzole (current standard) |
|---|---|---|---|
| What it is | An oral tyrosine kinase inhibitor (masitinib) added to standard riluzole | Placebo added to standard riluzole | Riluzole monotherapy is the established disease‑modifying treatment for ALS |
| Role in trial | Investigational arm receiving masitinib plus riluzole | Placebo control on riluzole background | Current standard ALS care outside trial |
| Primary use | To slow functional decline in ALS when added to riluzole | Control for assessment of masitinib effect | Approved disease‑modifying treatment to modestly slow ALS progression |
| Administration | Oral masitinib titrated to 4.5 or 6.0 mg/kg/day alongside oral riluzole | Oral placebo alongside oral riluzole | Oral riluzole per standard dosing |
| Evidence status | Phase 3 trial ongoing; prior phase 2/3 subgroup benefited with slowed decline and increased survival | Used as a control; no independent efficacy | Demonstrated modest survival benefit in ALS |
| Important risks | Safety profile includes risk of serious adverse events; prior trials reported dose‑reductions and rare ischemic and hepatic events | Safety reflects riluzole alone; placebo adds no treatment risk | Generally well‑tolerated; liver enzyme elevations are known adverse effect |
| Important limitations | Benefit shown only in subgroup with mild/moderate progression; full population outcomes pending | No therapeutic effect; used solely for comparison | Provides only modest survival benefit; many patients still decline over time |
| Patient impact | Potential for extended survival and slower decline in function in selected subgroup | No added benefit beyond riluzole | Provides modest slowing of progression with small survival improvement |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 weeks
Participants undergo a 12-week run-in period to confirm ALSFRS-R score progression before randomization.
Visits as needed to monitor ALSFRS-R progression
Duration - 48 weeks
Participants receive masitinib or placebo orally twice daily alongside riluzole, with dose escalations subject to safety controls.
Regular visits for dose escalation and safety monitoring during treatment
Duration - Up to 36 months
Participants are monitored for disease progression or survival for up to 36 months after treatment start.
Visits to assess progression-free survival and other outcomes
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Bethany D Latham, D Spencer Oskin, Rachel D Crouch...
https://pubmed.ncbi.nlm.nih.gov/36048877/AB Science
Lead Sponsor